MyoKardia Announces Proposed Public Offering of Common Stock
25 mars 2019 16h01 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
MyoKardia to Present at Cowen & Co. 39th Annual Health Care Conference
06 mars 2019 08h00 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious...
MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM
04 mars 2019 08h02 HE
|
MyoKardia, Inc.
Mavacamten Well Tolerated; Results Show Statistically Significant Elimination of Obstruction and Durable NYHA Class Improvements Statistically Significant Improvement in Several Key Biomarkers...
MyoKardia Reports Fourth Quarter and Full Year 2018 Financial Results
28 févr. 2019 08h30 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
MyoKardia Appoints William Fairey as Chief Commercial Officer
23 janv. 2019 08h30 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference
03 janv. 2019 08h00 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi
02 janv. 2019 08h00 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients
11 déc. 2018 08h30 HE
|
MyoKardia, Inc.
MYK-491 Demonstrated Increase in Contractility Consistent with Data from Preclinical and Healthy Volunteer Studies Multiple-Ascending Dose Phase 2a Clinical Trial in DCM and Systolic Heart Failure...
MyoKardia to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
05 déc. 2018 16h01 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions
12 nov. 2018 07h30 HE
|
MyoKardia, Inc.
Improved Left Ventricular Compliance Demonstrated in Genetic Pig Model of Non-Obstructed Hypertrophic Cardiomyopathy Results Add to Growing Body of Evidence of Mavacamten’s Dual Activity in...